Zacks Research Issues Negative Estimate for IQVIA Earnings

Key Points

• Zacks Research has lowered Q1 2027 earnings estimates for IQVIA from $2.91 to $2.81 per share, while the full-year consensus estimate is $10.84 per share.
• Various analysts have recently adjusted their ratings on IQVIA, with Evercore ISI raising its target price to $180.00 and HSBC cutting its rating to "hold" and target price to $160.00.
• Despite the recent downgrade, IQVIA shares are currently rated as a "Moderate Buy" on average, with a target price of $228.62.

IQVIA Holdings Inc. (NYSE:IQV - Free Report) - Equities researchers at Zacks Research reduced their Q1 2027 earnings estimates for shares of IQVIA in a research note issued on Tuesday, August 12th. Zacks Research analyst R. Department now expects that the medical research company will post earnings of $2.81 per share for the quarter, down from their previous estimate of $2.91. The consensus estimate for IQVIA's current full-year earnings is $10.84 per share.

Several other research firms have also recently issued reports on IQV. Evercore ISI boosted their target price on shares of IQVIA from $170.00 to $180.00 and gave the company an "outperform" rating in a research note on Wednesday, July 9th. Hsbc Global Res cut shares of IQVIA from a "strong-buy" rating to a "hold" rating in a research report on Friday, April 25th. Citigroup restated a "neutral" rating on shares of IQVIA in a research report on Thursday, May 22nd. HSBC cut shares of IQVIA from a "buy" rating to a "hold" rating and reduced their target price for the company from $260.00 to $160.00 in a research report on Friday, April 25th. Finally, Redburn Partners set a $188.00 target price on shares of IQVIA in a research report on Friday, May 23rd. Seven analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $228.62.

IQVIA Stock Performance

Shares of IQV traded down $2.61 during trading hours on Thursday, hitting $187.62. The stock had a trading volume of 173,368 shares, compared to its average volume of 1,990,464. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.84 and a current ratio of 0.84. The firm has a 50-day moving average price of $168.77 and a 200 day moving average price of $169.04. IQVIA has a fifty-two week low of $134.65 and a fifty-two week high of $252.88. The firm has a market capitalization of $31.90 billion, a price-to-earnings ratio of 27.17, a PEG ratio of 2.04 and a beta of 1.30.

IQVIA (NYSE:IQV - Get Free Report) last posted its earnings results on Tuesday, July 22nd. The medical research company reported $2.81 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.77 by $0.04. IQVIA had a net margin of 7.88% and a return on equity of 30.05%. The firm had revenue of $4.02 billion during the quarter, compared to analysts' expectations of $3.96 billion. During the same period in the previous year, the business posted $2.64 EPS. The business's revenue was up 5.3% compared to the same quarter last year.

Insiders Place Their Bets

In other IQVIA news, insider Keriann Cherofsky sold 549 shares of the firm's stock in a transaction on Wednesday, July 23rd. The stock was sold at an average price of $191.53, for a total value of $105,149.97. Following the completion of the sale, the insider owned 2,910 shares of the company's stock, valued at approximately $557,352.30. This trade represents a 15.87% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Eric Sherbet sold 5,800 shares of the firm's stock in a transaction on Wednesday, July 23rd. The shares were sold at an average price of $190.05, for a total value of $1,102,290.00. Following the completion of the sale, the insider directly owned 27,178 shares of the company's stock, valued at approximately $5,165,178.90. This trade represents a 17.59% decrease in their position. The disclosure for this sale can be found here. Company insiders own 1.60% of the company's stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. Sowell Financial Services LLC acquired a new position in IQVIA in the 1st quarter valued at about $305,000. Mather Group LLC. raised its stake in IQVIA by 83.5% in the 1st quarter. Mather Group LLC. now owns 769 shares of the medical research company's stock valued at $136,000 after purchasing an additional 350 shares during the last quarter. Private Advisor Group LLC raised its stake in IQVIA by 11.6% in the 1st quarter. Private Advisor Group LLC now owns 5,435 shares of the medical research company's stock valued at $958,000 after purchasing an additional 566 shares during the last quarter. Park Avenue Securities LLC grew its holdings in IQVIA by 40.4% in the 1st quarter. Park Avenue Securities LLC now owns 5,425 shares of the medical research company's stock valued at $956,000 after buying an additional 1,562 shares during the period. Finally, Wealth Enhancement Advisory Services LLC grew its holdings in IQVIA by 34.5% in the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 13,259 shares of the medical research company's stock valued at $2,338,000 after buying an additional 3,398 shares during the period. Institutional investors and hedge funds own 89.62% of the company's stock.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.